according to the Hazardous Products Regulations



Zilpaterol Formulation

Version Revision Date: SDS Number: Date of last issue: 04/14/2025 6.2 06/05/2025 29168-00027 Date of first issue: 11/07/2014

SECTION 1. IDENTIFICATION

Product name : Zilpaterol Formulation Other means of identification : No data available

Manufacturer or supplier's details

Company name of supplier : Merck & Co., Inc Address : 37 McCarville Street

Charlottetown, PE C1E 2A7

Telephone : 908-740-4000 Emergency telephone : 1-908-423-6000

E-mail address : EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the Hazardous Products Regulations

Specific target organ toxicity : Category 1 (Cardio-vascular system, Central nervous system,

repeated exposure

Lungs)

GHS label elements

Hazard pictograms

Signal Word : Danger

Hazard Statements : H372 Causes damage to organs (Cardio-vascular system, Cen-

tral nervous system, Lungs) through prolonged or repeated ex-

posure.

Precautionary Statements : Prevention:

P260 Do not breathe dust.

P264 Wash skin thoroughly after handling.

P270 Do not eat, drink or smoke when using this product.

Response:

P314 Get medical attention if you feel unwell.

Disposal:

P501 Dispose of contents and container to an approved waste

disposal plant.

according to the Hazardous Products Regulations



Zilpaterol Formulation

Version Revision Date: SDS Number: Date of last issue: 04/14/2025 6.2 06/05/2025 29168-00027 Date of first issue: 11/07/2014

Other hazards

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	Common CAS-No.		Concentration (% w/w)	
	Name/Synonym			
Zilpaterol	No data availa- ble	119520-06-8	>= 1 - < 5 *	

^{*} Actual concentration or concentration range is withheld as a trade secret

SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical

advice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled : If inhaled, remove to fresh air.

Get medical attention if symptoms occur.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty

of water.

Get medical attention if symptoms occur.

In case of eye contact : If in eyes, rinse well with water.

Get medical attention if irritation develops and persists.

If swallowed, DO NOT induce vomiting.

Get medical attention if symptoms occur. Rinse mouth thoroughly with water.

Most important symptoms : C

and effects, both acute and

delayed

Contact with dust can cause mechanical irritation or drying of

the skin.

Dust contact with the eyes can lead to mechanical irritation.

Causes damage to organs through prolonged or repeated

exposure.

Protection of first-aiders : First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

Specific hazards during fire : Avoid generating dust; fine dust dispersed in air in sufficient

according to the Hazardous Products Regulations



Zilpaterol Formulation

Version Revision Date: SDS Number: Date of last issue: 04/14/2025 6.2 06/05/2025 29168-00027 Date of first issue: 11/07/2014

fighting concentrations, and in the presence of an ignition source is a

potential dust explosion hazard.

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod-

ucts

Carbon oxides

Nitrogen oxides (NOx)

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

Special protective equipment :

for fire-fighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emer-

gency procedures

Use personal protective equipment.

Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for containment and cleaning up

Sweep up or vacuum up spillage and collect in suitable

container for disposal.

Avoid dispersal of dust in the air (i.e., clearing dust surfaces

with compressed air).

Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items

employed in the cleanup of releases. You will need to

determine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures : Static electricity may accumulate and ignite suspended dust

causing an explosion.

Provide adequate precautions, such as electrical grounding

and bonding, or inert atmospheres.

Local/Total ventilation

Use only with adequate ventilation.

Advice on safe handling : Do not breathe dust.

according to the Hazardous Products Regulations



Zilpaterol Formulation

Version Revision Date: SDS Number: Date of last issue: 04/14/2025 6.2 06/05/2025 29168-00027 Date of first issue: 11/07/2014

Do not swallow.

Avoid contact with eyes.

Avoid prolonged or repeated contact with skin.

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure

assessment

Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition.

Take precautionary measures against static discharges. Do not eat, drink or smoke when using this product.

Take care to prevent spills, waste and minimize release to the

environment.

Conditions for safe storage : Keep in properly labeled containers.

Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:

Strong oxidizing agents

Self-reactive substances and mixtures

Organic peroxides

Explosives Gases

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Zilpaterol	119520-06-8	TWA	1 μg/m3 (OEB 4)	Internal
		Wipe limit	10 μg/100 cm2	Internal

Engineering measures

The information below is intended for larger pilot/commercial-scale operations and manufacturing. For smaller scale, clinical, or pharmacy settings, site-specific internal risk assessment practices should be conducted to determine appropriate exposure control measures. The health hazard risks of handling this material are dependent on multiple factors, including but not limited to physical form and quantity handled. If applicable, use process enclosures, local exhaust ventilation (e.g., Biosafety Cabinet, Ventilated Balance Enclosures), or other engineering controls to maintain airborne levels below recommended exposure limits. If exposure limits have not been established, maintain airborne levels as low as reasonably achievable.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., vacuum conveying from a closed system, packout head with inflatable seal from

stationary container, ventilated enclosure, etc.).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to

according to the Hazardous Products Regulations



Zilpaterol Formulation

Version Revision Date: SDS Number: Date of last issue: 04/14/2025 6.2 06/05/2025 29168-00027 Date of first issue: 11/07/2014

protect products, workers, and the environment.

Essentially no open handling permitted.

Use closed processing systems or containment technologies.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or

exposure assessment demonstrates exposures outside the

recommended guidelines, use respiratory protection.

Filter type

Hand protection

Particulates type

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Skin and body protection : Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets,

disposable suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

Hygiene measures : If exposure to chemical is likely during typical use, provide

eye flushing systems and safety showers close to the

working place.

When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : powder

Color : tan

Odor : No data available

Odor Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling :

range

No data available

according to the Hazardous Products Regulations



Zilpaterol Formulation

Version Revision Date: SDS Number: Date of last issue: 04/14/2025 6.2 06/05/2025 29168-00027 Date of first issue: 11/07/2014

Flash point : Not applicable

Evaporation rate : Not applicable

Flammability (solid, gas) : May form explosive dust-air mixture during processing,

handling or other means.

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapor pressure : Not applicable

Relative vapor density : Not applicable

Relative density : No data available

Density : No data available

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-

octanol/water

: Not applicable

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, dynamic : No data available

Viscosity, kinematic : Not applicable

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle characteristics

Particle size : No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard. Chemical stability : Stable under normal conditions.

Possibility of hazardous reac- : May form explosive dust-air mixture during processing,

according to the Hazardous Products Regulations



Zilpaterol Formulation

Version Revision Date: SDS Number: Date of last issue: 04/14/2025 6.2 06/05/2025 29168-00027 Date of first issue: 11/07/2014

tions handling or other means.

Can react with strong oxidizing agents.

Conditions to avoid : Heat, flames and sparks.

Avoid dust formation.

Incompatible materials : Oxidizing agents

Hazardous decomposition : No haza

products

omposition : No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure

Inhalation Skin contact Ingestion Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity : Acute toxicity estimate: > 2,000 mg/kg

Method: Calculation method

Acute inhalation toxicity : Acute toxicity estimate: > 5 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist Method: Calculation method

Components:

Zilpaterol:

Acute oral toxicity : LD50 (Mouse, male and female): 430 - 580 mg/kg

LD50 (Rat, male and female): 890 - 1,325 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

Symptoms: Tremors, Breathing difficulties

Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg

Acute toxicity (other routes of :

TDLo (Rabbit): 9.6 %

administration)

Application Route: see user defined free text

Symptoms: Increased pulse rate

Skin corrosion/irritation

Not classified based on available information.

Components:

Zilpaterol:

according to the Hazardous Products Regulations



Zilpaterol Formulation

Version Revision Date: SDS Number: Date of last issue: 04/14/2025 6.2 06/05/2025 29168-00027 Date of first issue: 11/07/2014

Species : Rabbit

Result : No skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Zilpaterol:

Species : Rabbit

Result : Mild eye irritation

Respiratory or skin sensitization

Skin sensitization

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Components:

Zilpaterol:

Test Type : Maximization Test

Species : Guinea pig

Assessment : Does not cause skin sensitization.

Result : negative

Germ cell mutagenicity

Not classified based on available information.

Components:

Zilpaterol:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Test system: Chinese hamster ovary cells

Result: negative

Test Type: Mouse Lymphoma Test system: mouse lymphoma cells

Result: negative

Test Type: unscheduled DNA synthesis assay

Test system: rat hepatocytes

Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test

Species: Mouse

Application Route: Oral

Result: negative

according to the Hazardous Products Regulations



Zilpaterol Formulation

Version Revision Date: SDS Number: Date of last issue: 04/14/2025 6.2 06/05/2025 29168-00027 Date of first issue: 11/07/2014

Test Type: in vivo assay

Species: Mouse

Cell type: Bone marrow Application Route: Oral Result: negative

Carcinogenicity

Not classified based on available information.

Components:

Zilpaterol:

Species : Rat, male and female

Application Route : oral (feed) Exposure time : 104 weeks

0.05 mg/kg body weight0.125 mg/kg body weight

Result : negative Target Organs : Ovary

Species : Mouse
Application Route : Oral
Exposure time : 18 Months

0.02 mg/kg body weight0.05 mg/kg body weight

Result : negative Target Organs : Blood

Reproductive toxicity

Not classified based on available information.

Components:

Zilpaterol:

Effects on fertility : Test Type: Two-generation study

Species: Rat, male

Application Route: oral (feed)

Fertility: NOAEL: 1.8 mg/kg body weight

Result: No effects on fertility and early embryonic

development were detected.

Test Type: Two-generation study

Species: Rat, male

Application Route: oral (feed)

Fertility: NOAEL: 0.94 mg/kg body weight Result: No effects on fertility and early embryonic

development were detected.

Effects on fetal development : Test Type: Embryo-fetal development

Species: Rat, female Application Route: Oral

Developmental Toxicity: NOAEL: 10 mg/kg body weight

according to the Hazardous Products Regulations



Zilpaterol Formulation

Version Revision Date: SDS Number: Date of last issue: 04/14/2025 6.2 06/05/2025 29168-00027 Date of first issue: 11/07/2014

Embryo-fetal toxicity.: LOAEL: 50 mg/kg body weight Result: No teratogenic effects., Embryotoxic effects and adverse effects on the offspring were detected only at high

maternally toxic doses

STOT-single exposure

Not classified based on available information.

STOT-repeated exposure

Causes damage to organs (Cardio-vascular system, Central nervous system, Lungs) through prolonged or repeated exposure.

Components:

Zilpaterol:

Target Organs : Cardio-vascular system, Central nervous system, Lungs
Assessment : Causes damage to organs through prolonged or repeated

exposure.

Repeated dose toxicity

Components:

Zilpaterol:

Species : Monkey
NOAEL : 0.01 mg/kg
LOAEL : 0.05 mg/kg
Application Route : Oral
Exposure time : 4 Weeks

Target Organs : Cardio-vascular system

Symptoms : Increased pulse rate, Lowered blood pressure

Species : Rat, male and female

LOAEL : 0.05 mg/kg
Application Route : Oral
Exposure time : 13 Weeks

Target Organs : Cardio-vascular system Symptoms : Lowered blood pressure

Species : Pig, male and female

NOAEL : 0.05 mg/kg LOAEL : 1 mg/kg Application Route : Oral Exposure time : 13 Weeks Target Organs : Heart

Species : Rat, male and female

NOAEL : 0.250 mg/kg
Application Route : oral (feed)
Exposure time : 52 Weeks

Target Organs : Cardio-vascular system

Symptoms : slow pulse

Species : Dog

according to the Hazardous Products Regulations



Zilpaterol Formulation

Version Revision Date: SDS Number: Date of last issue: 04/14/2025 6.2 06/05/2025 29168-00027 Date of first issue: 11/07/2014

Application Route : Dermal

Remarks : No significant adverse effects were reported

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Zilpaterol:

Ingestion : Target Organs: Lungs

Symptoms: Tremors, Increased pulse rate Target Organs: Central nervous system

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Zilpaterol:

Toxicity to algae/aquatic

plants

NOEC (Pseudokirchneriella subcapitata (green algae)): 100

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Remarks: No toxicity at the limit of solubility.

EC50 (Pseudokirchneriella subcapitata (green algae)): > 100

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Remarks: No toxicity at the limit of solubility.

Persistence and degradability

Components:

Zilpaterol:

Stability in water : Hydrolysis: 0 %(5 d)

Bioaccumulative potential

Components:

Zilpaterol:

Partition coefficient: n-

: log Pow: 1

octanol/water

Mobility in soil

Components:

Zilpaterol:

according to the Hazardous Products Regulations



Zilpaterol Formulation

Version 6.2

Revision Date: 06/05/2025

SDS Number: 29168-00027

Date of last issue: 04/14/2025 Date of first issue: 11/07/2014

Distribution among environ-

mental compartments

log Koc: 2.8

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Do not dispose of waste into sewer.

Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste

handling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation

TDG

Not regulated as a dangerous good

Special precautions for user

Not applicable

SECTION 15. REGULATORY INFORMATION

The ingredients of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

SECTION 16. OTHER INFORMATION

Full text of other abbreviations

according to the Hazardous Products Regulations



Zilpaterol Formulation

Version **Revision Date:** SDS Number: Date of last issue: 04/14/2025 06/05/2025 29168-00027 Date of first issue: 11/07/2014 6.2

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation: DSL - Domestic Substances List (Canada): ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization: ISHL - Industrial Safety and Health Law (Japan): ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Sources of key data used to

Revision Date 06/05/2025 Date format mm/dd/yyyy

compile the Material Safety

eChem Portal search results and European Chemicals Agen-**Data Sheet** cy, http://echa.europa.eu/

Internal technical data, data from raw material SDSs, OECD

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

CA / Z8